CLS Holdings plc (LON:CLI – Get Free Report) declared a dividend on Tuesday, April 1st, DividendData.Co.Uk reports. Stockholders of record on Thursday, April 10th will be paid a dividend of GBX 2.68 ($0.03) per share on Friday, May 23rd. This represents a dividend yield of 4.17%. The ex-dividend date is Thursday, April 10th. This is a 3.1% increase from CLS’s previous dividend of $2.60. The official announcement can be seen at this link.
CLS Stock Up 2.9 %
Shares of CLI opened at GBX 62.89 ($0.80) on Tuesday. The stock has a market capitalization of £250.61 million, a price-to-earnings ratio of -1.21 and a beta of 1.01. CLS has a 52 week low of GBX 60.91 ($0.78) and a 52 week high of GBX 101.40 ($1.29). The company has a debt-to-equity ratio of 123.30, a quick ratio of 0.59 and a current ratio of 0.73. The stock has a fifty day moving average of GBX 71.06 and a 200-day moving average of GBX 80.91.
CLS (LON:CLI – Get Free Report) last released its quarterly earnings results on Tuesday, April 1st. The company reported GBX (23.60) (($0.30)) earnings per share for the quarter. CLS had a negative return on equity of 23.42% and a negative net margin of 134.11%. As a group, sell-side analysts anticipate that CLS will post 10.0104167 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
CLS Company Profile
We are a commercial property investment company with a £2.1bn portfolio listed on the Premium Main Market on the London Stock Exchange, specialising in future-focused office space in the UK, Germany and France. Through geographical diversification, local expertise and an active management approach, we transform office properties into sustainable, modern spaces that help our tenants’ businesses to grow.
Featured Articles
- Five stocks we like better than CLS
- What is a Secondary Public Offering? What Investors Need to Know
- Who Led Buybacks to End 2024? Hint: It Wasn’t Big Tech
- What Are Dividend Achievers? An Introduction
- Alibaba Caught in Tariff Crossfire: Is It Time to Buy?
- With Risk Tolerance, One Size Does Not Fit All
- Can Solid Biosciences Challenge Sarepta in the DMD Market?
Receive News & Ratings for CLS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CLS and related companies with MarketBeat.com's FREE daily email newsletter.